Biology subjects

Kim, S. O.

Publications and source records attributed to Kim, S. O..

4 recordsLinked to original sources

bioRxiv2025

Resolving Inflammation: The Impact of Antiretroviral Therapy on Macrophage Traffic In and Out of the CNS.

The effect of antiretroviral therapy (ART) and therapy interruption on myeloid cell traffic out of the central nervous system (CNS) with human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) infection are understudied. Using intracisternal (i.c.) injection of dual-colored fluorescent superparamagnetic iron oxide nanoparticles (SPION) in SIV-infected macaques early (12-14 dpi) and late (30 days before sacrifice) we studied CNS macrophage viral infection, turnover, and traffic out. SPION are preferentially taken up by perivascular, meningeal, and choroid plexus macrophages. In non-infected macaques, SPION+ macrophages can traffic out of the CNS to the periphery (deep cervical lymph node (dcLN), spleen, and dorsal root ganglia (DRG)), but accumulate in the CNS with SIV infection. ART reduces the accumulation of CNS SPION+ perivascular macrophages but not meningeal or choroid plexus macrophages. ART interruption does not affect the number of SPION+ perivascular and choroid plexus but the number of SPION+ meningeal macrophages increase. ART eliminates SIV-RNA perivascular macrophages, but few scattered RNA+ macrophages in the meninges and choroid plexus remain. With ART interruption, perivascular macrophages remain SIV-but scattered SIV+ meningeal and choroid plexus macrophages exist. In non-infected animals SPION+ macrophages traffic to dcLN, spleen, and DRG at a rate that is decreased with SIV infection and AIDS. SIV- RNA+ SPION+ macrophages that traffic out of the CNS are eliminated by ART and do not rebound with ART interruption. Using two different colored SPION to study the establishment of CNS SIV viral reservoirs, we find greater numbers of early SPION+ macrophages within and outside of the CNS with SIVE, ART, and ART interruption. These data are consistent with SIV-infected perivascular macrophages establishing an early viral reservoir, and continual viral seeding of the meninges and choroid plexus during infection. These findings are consistent with ART reducing traffic of infected macrophages out of the CNS, clearing the CNS perivascular macrophage viral reservoir but not SIV-RNA+ macrophages in meninges and choroid plexus that can rebound with ART interruption.

immunology↗

bioRxiv2024

Inhibition of the transcription factor PU.1 suppresses tumor growth in mice by promoting the recruitment of cytotoxic lymphocytes through the CXCL9-CXCR3 axis

Tumor-associated macrophages (TAMs) are among the most abundant immune cells associated with tumors, which often exhibit immune regulatory phenotypes that promote tumor growth and confer resistance to anti-tumor immune therapies. Despite extensive efforts in developing immunotherapeutic strategies aimed at controlling the recruitment or reprogramming of TAMs, success has been limited due to strategic caveats, underscoring the need for a novel approach targeting the TAMs. PU.1, a lineage-dependent transcription factor, is highly expressed throughout the lifespan of macrophages. We have found that inhibition of PU.1 by the small molecule DB2313 suppresses melanoma tumor growth in mice through enhanced tumor recruitment of CD4+ T helper cells and cytotoxic T/NK cells mediated by TAMs. Whole transcriptome and targeted gene expression analyses revealed that DB2313 upregulates CXCL9 expression in bone marrow-derived macrophages (BMDMs) and TAMs. The anti-tumor effects of DB2313 were abolished by depleting macrophages with clodronate or inhibiting the CXCL9-CXCR3 chemokine axis using neutralizing antibodies against CXCL9 or CXCR3. Collectively, these results suggest that pharmacological inhibition of PU.1 suppresses tumor growth by promoting tumor infiltrating lymphocytes through the CXCL9-CXCR3 chemokine axis. Our study establishes a framework for developing TAM-modulating immunotherapies by targeting the transcriptional factor PU.1.

immunology↗

bioRxiv2020

Elements at the 5' end of Xist harbor SPEN-independent transcriptional antiterminator activity

The Xist lncRNA requires Repeat A, a conserved RNA element located in its 5' end, to induce gene silencing during X-chromosome inactivation. Intriguingly, Repeat A is also required for the production of Xist. While silencing by Repeat A requires the protein SPEN, how Repeat A promotes Xist production remains unclear. We report that in mouse embryonic stem cells, expression of a transgene comprising the first two kilobases of Xist (Xist-2kb) causes transcriptional readthrough of multiple downstream polyadenylation sequences. Readthrough required Repeat A and the ~750 nucleotides downstream but did not require SPEN. Despite associating with SPEN and chromatin, Xist-2kb did not robustly silence transcription, whereas a transgene comprising Xists first 5.5 kilobases robustly silenced transcription and read through its polyadenylation sequence. Longer, spliced Xist transgenes also induced robust silencing yet terminated efficiently. Thus, in contexts examined here, Xist requires sequence elements beyond its first two kilobases to robustly silence transcription, and the 5' end of Xist harbors SPEN-independent transcriptional antiterminator activity that can repress proximal cleavage and polyadenylation. In endogenous contexts, this antiterminator activity may help produce full-length Xist RNA while rendering the Xist locus resistant to silencing by the same repressive complexes that the lncRNA recruits to other genes.

molecular biology↗

bioRxiv2018

A piggyBac-based toolkit for inducible genome editing in mammalian cells

We describe the development and application of a novel series of vectors that facilitate CRISPR-Cas9-mediated genome editing in mammalian cells, which we call CRISPR-Bac. CRISPR-Bac leverages the piggyBac transposon to randomly insert CRISPR-Cas9 components into mammalian genomes. In CRISPR-Bac, a single piggyBac cargo vector containing a doxycycline-inducible Cas9 or catalytically-dead Cas9 (dCas9) variant and a gene conferring resistance to Hygromycin B is co-transfected with a plasmid expressing the piggyBac transposase. A second cargo vector, expressing a single-guide RNA (sgRNA) of interest, the reverse-tetracycline TransActivator (rtTA), and a gene conferring resistance to G418, is also cotransfected. Subsequent selection on Hygromycin B and G418 generates polyclonal cell populations that stably express Cas9, rtTA, and the sgRNA(s) of interest. Using Mus musculus-derived embryonic and trophoblast stem cells, we show that CRISPR-Bac can be used to knockdown proteins of interest, to create targeted genetic deletions with high efficiency, and to activate or repress transcription of protein-coding genes and an imprinted long noncoding RNA. The ratio of sgRNA-to-Cas9-to-transposase can be adjusted in transfections to alter the average number of cargo insertions into the genome. sgRNAs targeting multiple genes can be inserted in a single transfection. CRISPR-Bac is a versatile platform for genome editing that simplifies the generation of mammalian cells that stably express the CRISPR-Cas9 machinery.

molecular biology↗